Page 137 - 《中国药房》2023年1期

2020，18（1）：92. cing of tissue factor suppresses metastasis and prevents
[20] DU W，CHEN C，SUN P，et al. Eliciting an immune hot cancer-associated hypercoagulability[J]. Nano Lett，2019，
tumor niche with biomimetic drug-based multi-functional 19（7）：4721-4730.
nanohybrids augments immune checkpoint blockade- [33] LI G，GAO Y，GONG C，et al. Dual-blockade immune
based breast cancer therapy[J]. Nanoscale，2020，12（5）： checkpoint for breast cancer treatment based on a tumor-
3317-3329. penetrating peptide assembling nanoparticle[J]. ACS Appl
[21] MEI D，GONG L，ZOU Y，et al. Platelet membrane- Mater Interfaces，2019，11（43）：39513-39524.
cloaked paclitaxel-nanocrystals augment postoperative [34] ZHANG L，MU C，ZHANG T，et al. Development of tar‐
chemotherapeutical efficacy[J]. J Control Release，2020， geted therapy therapeutics to sensitize triple-negative
324：341-353. breast cancer chemosensitivity utilizing bacteriophage
[22] LI J Q，ZHAO R X，YANG F M，et al. An erythrocyte phi29 derived packaging RNA[J]. J Nanobiotechnology，
membrane-camouflaged biomimetic nanoplatform for en‐ 2021，19（1）：13.
hanced chemo-photothermal therapy of breast cancer[J]. J [35] ZHANG L，MU C，ZHANG T，et al. Systemic delivery of
Mater Chem B，2022，10（12）：2047-2056. aptamer-conjugated XBP1 siRNA nanoparticles for effi‐
[23] LI S，WU Y，DING F，et al. Engineering macrophage- cient suppression of HER2+ breast cancer[J]. ACS Appl
derived exosomes for targeted chemotherapy of triple- Mater Interfaces，2020，12（29）：32360-32371.
negative breast cancer[J]. Nanoscale，2020，12（19）： [36] ZHAO L，GU C，GAN Y，et al. Exosome-mediated siRNA
10854-10862. delivery to suppress postoperative breast cancer metastasis
[24] HU M，ZHANG J，KONG L，et al. Immunogenic hybrid [J]. J Control Release，2020，318：1-15.
nanovesicles of liposomes and tumor-derived nanovesicles [37] HA M，NAM S H，SIM K，et al. Highly efficient photo‐
for cancer immunochemotherapy[J]. ACS Nano，2021，15 thermal therapy with cell-penetrating peptide-modified
（2）：3123-3138. bumpy Au triangular nanoprisms using low laser power
[25] ZHAO Z，LI Y，SHUKLA R，et al. Development of a bio‐ and low probe dose[J]. Nano Lett，2021，21（1）：731-739.
compatible copolymer nano complex to deliver VEGF [38] TAHERI-LEDARI R，ZHANG W，RADMANESH M，et
siRNA for triple negative breast cancer[J]. Theranostics， al. Multi-stimuli nanocomposite therapeutic：docetaxel tar‐
2019，9（15）：4508-4524. geted delivery and synergies in treatment of human breast
[26] JUNEJA R，VADAREVU H，HALMAN J，et al. Combina‐ cancer tumor[J]. Small，2020，16（41）：e2002733.
tion of nucleic acid and mesoporous silica nanoparticles： [39] LI L，FU J，WANG X Y，et al. Biomimetic “nanoplate‐
optimization and therapeutic performance in vitro[J]. ACS lets” as a targeted drug delivery platform for breast cancer
Appl Mater Interfaces，2020，12（35）：38873-38886. theranostics[J]. ACS Appl Mater Interfaces，2021，13（3）：
[27] ZHANG Y，TENG Z，NI Q，et al. Orderly curled silica 3605-3621.
nanosheets with a small size and macromolecular loading [40] ZHOU M，XING Y，LI X，et al. Cancer cell membrane
pores：synthesis and delivery of macromolecules to eradi‐ camouflaged semi-Yolk@Spiky-shell nanomotor for en‐
cate drug-resistant cancer[J]. ACS Appl Mater Interfaces， hanced cell adhesion and synergistic therapy[J]. Small，
2020，12（52）：57810-57820. 2020，16（39）：e2003834.
[28] JIN M，HOU Y，QUAN X，et al. Smart polymeric [41] CHEN Y，ZHANG X H，CHENG D B，et al. Near-
nanoparticles with pH-responsive and PEG-detachable infrared laser-triggered in situ dimorphic transformation
properties （Ⅱ）：co-delivery of paclitaxel and VEGF of BF2-azadipyrromethene nanoaggregates for enhanced
siRNA for synergistic breast cancer therapy in mice[J]. Int solid tumor penetration[J]. ACS Nano，2020，14（3）：3640-
J Nanomedicine，2021，16：5479-5494. 3650.
[29] LIU H，LIU C，YE L，et al. Nanoassemblies with effective [42] ZHANG Y，WANG Q，MA T，et al. Tumor targeted com‐
serum tolerance capability achieving robust gene silencing bination therapy mediated by functional macrophages un‐
efficacy for breast cancer gene therapy[J]. Adv Mater， der fluorescence imaging guidance[J]. J Control Release，
2021，33（7）：e2003523. 2020，328：127-140.
[30] LI Y，DING J，XU X，et al. Dual hypoxia-targeting RNAi [43] QIAO J，TIAN F，DENG Y，et al. Bio-orthogonal click-
nanomedicine for precision cancer therapy[J]. Nano Lett， targeting nanocomposites for chemo-photothermal syner‐
2020，20（7）：4857-4863. gistic therapy in breast cancer[J]. Theranostics，2020，10
[31] XU J，LIU Y，LI Y，et al. Precise targeting of POLR2A as （12）：5305-5321.
a therapeutic strategy for human triple negative breast can‐ [44] LIU R，AN Y，JIA W，et al. Macrophage-mimic shape
cer[J]. Nat Nanotechnol，2019，14（4）：388-397. changeable nanomedicine retained in tumor for multi‐
[32] LIU S，ZHANG Y，ZHAO X，et al. Tumor-specific silen- modal therapy of breast cancer[J]. J Control Release，

中国药房 2023年第34卷第1期 China Pharmacy 2023 Vol. 34 No. 1 · 127 ·